Hans Henrik Parving

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. pmc A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
    Peter Lommer Kristensen
    Department of Cardiology, Nephrology and Endocrinology, Hillerød University Hospital, Dyrehavevej 29, DK 3400, Hillerød, Denmark
    BMC Endocr Disord 12:10. 2012
  2. doi request reprint Cardiorenal end points in a trial of aliskiren for type 2 diabetes
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 367:2204-13. 2012
  3. ncbi request reprint Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Denmark
    J Renin Angiotensin Aldosterone Syst 13:387-93. 2012
  4. pmc The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes
    Amélie Dendooven
    Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
    J Negat Results Biomed 10:4. 2011
  5. pmc Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
    Sten Andersen
    Steno Diabetes Centre, Gentofte, Denmark
    BMC Nephrol 11:29. 2010
  6. pmc Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus
    YaoMin Hu
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    BMC Med Genomics 2:41. 2009
  7. ncbi request reprint Aliskiren combined with losartan in type 2 diabetes and nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark
    N Engl J Med 358:2433-46. 2008
  8. ncbi request reprint Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
    Hans Henrik Parving
    Steno Diabetes Center, Copenhagen, Denmark
    Semin Nephrol 24:147-57. 2004
  9. ncbi request reprint Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study
    H H Parving
    Steno Diabetes Center, Niels Steensensvej 2, DK 2820 Gentofte, Denmark
    QJM 98:119-26. 2005
  10. pmc ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
    J Am Soc Nephrol 19:771-9. 2008

Collaborators

Detail Information

Publications142 found, 100 shown here

  1. pmc A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
    Peter Lommer Kristensen
    Department of Cardiology, Nephrology and Endocrinology, Hillerød University Hospital, Dyrehavevej 29, DK 3400, Hillerød, Denmark
    BMC Endocr Disord 12:10. 2012
    ..abstract:..
  2. doi request reprint Cardiorenal end points in a trial of aliskiren for type 2 diabetes
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 367:2204-13. 2012
    ..This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both...
  3. ncbi request reprint Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Denmark
    J Renin Angiotensin Aldosterone Syst 13:387-93. 2012
    ..Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone...
  4. pmc The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes
    Amélie Dendooven
    Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands
    J Negat Results Biomed 10:4. 2011
    ..In conclusion, the -945GC SNP does not affect plasma CTGF levels, incidence and prognosis of diabetic nephropathy, and cardiovascular outcome...
  5. pmc Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
    Sten Andersen
    Steno Diabetes Centre, Gentofte, Denmark
    BMC Nephrol 11:29. 2010
    ..The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome...
  6. pmc Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus
    YaoMin Hu
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    BMC Med Genomics 2:41. 2009
    ....
  7. ncbi request reprint Aliskiren combined with losartan in type 2 diabetes and nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark
    N Engl J Med 358:2433-46. 2008
    ....
  8. ncbi request reprint Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
    Hans Henrik Parving
    Steno Diabetes Center, Copenhagen, Denmark
    Semin Nephrol 24:147-57. 2004
    ..The studies mentioned here suggest that ARB represents a beneficial treatment of hypertension and proteinuria in incipient and overt diabetic nephropathy...
  9. ncbi request reprint Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study
    H H Parving
    Steno Diabetes Center, Niels Steensensvej 2, DK 2820 Gentofte, Denmark
    QJM 98:119-26. 2005
    ..Retinopathy is the clinical hallmark of generalized microangiopathy in diabetes...
  10. pmc ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
    J Am Soc Nephrol 19:771-9. 2008
    ..In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan...
  11. ncbi request reprint [Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]
    Hans Henrik Parving
    Aarhus Universitet, Det Sundhedsvidenskabelige Fakultet, Steno Diabetes Center
    Ugeskr Laeger 171:881-4. 2009
    ..001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect...
  12. ncbi request reprint Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy
    Hans Henrik Parving
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Curr Hypertens Rep 4:387-93. 2002
    ..The renoprotective effects of these drugs are independent of their beneficial reduction in blood pressure...
  13. doi request reprint Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Nephrol Dial Transplant 24:1663-71. 2009
    ..Aliskiren a novel oral direct renin inhibitor that unlike ACEi and ARBs, lowers plasma renin activity, angiotensin I and angiotensin II levels, may thereby provide greater benefit compared to ACEi or ARB alone...
  14. ncbi request reprint Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 25:95-100. 2002
    ..g., lisinopril/enalapril at 20 mg daily. We tested the concept that such patients might benefit from dual blockade of the renin-angiotensin system (RAS)...
  15. ncbi request reprint Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Steen Andersen
    Steno Diabetes Center, Copenhagen, Denmark
    Diabetes Care 26:1501-6. 2003
    ..Therefore, we investigated the long-term effect of the angiotensin II subtype-1 (AT1) receptor antagonist losartan (100 mg o.d.) on kidney function in II and DD type 1 diabetic patients with diabetic nephropathy...
  16. pmc NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
    Henrik Reinhard
    Steno Diabetes Center, Niels Steensenvej 1, DK 2820 Gentofte, Denmark
    Cardiovasc Diabetol 11:19. 2012
    ....
  17. ncbi request reprint Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Steen Andersen
    Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Copenhagen, Denmark
    Kidney Int 62:192-8. 2002
    ..In an attempt to overcome this interaction, we evaluated the short-term renoprotective effect in diabetic nephropathy of the angiotensin II receptor antagonist losartan in patients homozygous for the insertion or the deletion allele...
  18. ncbi request reprint Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 63:1874-80. 2003
    ....
  19. ncbi request reprint Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Nephrol Dial Transplant 17:1019-24. 2002
    ..We tested the effect of dual blockade of the renin-angiotensin system (RAS) in these patients...
  20. pmc Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
    Søren S Lund
    Steno Diabetes Center, Gentofte, Denmark
    BMJ 339:b4324. 2009
    ..To study the effect of insulin treatment in combination with metformin or an insulin secretagogue, repaglinide, on glycaemic regulation in non-obese patients with type 2 diabetes...
  21. ncbi request reprint Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:1190-8. 2005
    ..The purpose of this study was to evaluate the renoprotective effect as reflected by short-term changes in albuminuria of ultrahigh doses of irbesartan in type 2 diabetic patients with microalbuminuria...
  22. pmc Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 32:1873-9. 2009
    ..We investigated whether the antiproteinuric effect of the direct renin inhibitor aliskiren is comparable to that of irbesartan and the effect of the combination...
  23. ncbi request reprint Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:2268-74. 2003
    ....
  24. ncbi request reprint Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Niels Steensensvej 2, DK 2820 Gentofte, Denmark
    Nephrol Dial Transplant 18:293-7. 2003
    ..We evaluated the time course of the antihypertensive and antialbuminuric effect after initiation of AT1 receptor blockade by losartan in diabetic nephropathy...
  25. ncbi request reprint Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease
    Stine E Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    J Renin Angiotensin Aldosterone Syst 14:161-6. 2013
    ..We investigated the effect of spironolactone added to standard RAAS blockade on these biomarkers in an analysis of four original studies...
  26. doi request reprint Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
    Søren S Lund
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Eur J Endocrinol 158:35-46. 2008
    ..Whether the same apply for postprandial glucose and lipid metabolism is unknown. Here, we compared the effect of metformin versus repaglinide on postprandial metabolism in non-obese T2DM patients...
  27. ncbi request reprint Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes
    Lise Tarnow
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 27:765-9. 2004
    ..This study investigated the relation between ADMA and diabetic micro- and macrovascular complications in a large cohort of type 1 diabetic patients with and without early diabetic nephropathy...
  28. ncbi request reprint Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    J Am Soc Nephrol 14:2843-50. 2003
    ..Interaction between polymorphisms in the renin-angiotensin system also influenced the loss of kidney function. This new genetic interaction model needs to be confirmed in future studies...
  29. ncbi request reprint Progression of nephropathy in type 2 diabetic patients
    Kasper Rossing
    Department of Physiology, Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 66:1596-605. 2004
    ....
  30. ncbi request reprint Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Maria Lajer
    Steno Diabetes Center, Niels Steensens Vej 1, 2820 Gentofte, Denmark
    Diabetes Care 31:747-52. 2008
    ....
  31. ncbi request reprint Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Diabetes Care 28:2106-12. 2005
    ....
  32. ncbi request reprint Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark and Faculty of Health Science, University of Aarhus, Denmark
    J Am Soc Nephrol 14:992-9. 2003
    ..All treatments were safe and well tolerated. In conclusion, dual blockade of the RAS may offer additional renal and cardiovascular protection in type I diabetic patients with DN...
  33. ncbi request reprint Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark Faculty of Health Science, University of Aarhus, Aarhus, Denmark
    Diabetes Care 26:150-5. 2003
    ..We evaluated the optimal dose of the angiotensin II receptor antagonist candesartan cilexetil for renoprotection as reflected by short-term changes in albuminuria in hypertensive type 2 diabetic patients with nephropathy...
  34. doi request reprint Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients
    Stine E Nielsen
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetes Res Clin Pract 97:71-6. 2012
    ..Our aim was to investigate u-NGAL, u-KIM1 and p-FGF23 and prediction of decline in kidney function in type 2 diabetic patients with proteinuria...
  35. doi request reprint Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function
    Maria Lajer
    Steno Diabetes Center, Gentofte, Denmark
    Platelets 21:525-32. 2010
    ..85) nor rate of decline in GFR (p = 0.69). Plasma sCD40L is elevated in T1DM nephropathy but is not a predictor of all-cause mortality, cardiovascular mortality and morbidity or deterioration of kidney function..
  36. pmc Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:2304-9. 2010
    ..This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD])...
  37. ncbi request reprint Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy
    Frederik Persson
    Steno Diabetes Center, Niels Steensenvej 2, DK 2820 Gentofte, Denmark
    Diabetes 55:3550-5. 2006
    ..04). There was no treatment effect on the other biomarkers. Irbesartan (300 mg once daily) reduces low-grade inflammation in this high-risk population, and this may reduce the risk of micro- and macrovascular disease...
  38. ncbi request reprint Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study
    Kasper Rossing
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetes Care 26:569-74. 2003
    ..In the present study, we evaluated 24-h blood pressure patterns in a subpopulation of the IRMA2 trial...
  39. ncbi request reprint Optimal dose of losartan for renoprotection in diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Copenhagen, Denmark
    Nephrol Dial Transplant 17:1413-8. 2002
    ..The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy...
  40. doi request reprint Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    J Renin Angiotensin Aldosterone Syst 13:250-3. 2012
    ..This post-hoc analysis assessed the influence of baseline glycaemic control on the reduction of albuminuria with aliskiren or placebo added to losartan in the Aliskiren in the EValuation of PrOteinuria In Diabetes (AVOID) study...
  41. pmc Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy
    Frederik Persson
    Steno Diabetes Center, Niels Steensensvej 1, DK 2820 Gentofte, Denmark
    Clin J Am Soc Nephrol 6:1025-31. 2011
    ..Our post hoc analysis assessed the baseline BP influence on the antiproteinuric effect in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study...
  42. pmc Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy
    Maria Lajer
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:1567-72. 2010
    ..The aim of this study was to investigate GDF-15 levels in relation to all-cause mortality, cardiovascular mortality and morbidity, decline in glomerular filtration rate (GFR), and progression toward end-stage renal disease (ESRD)...
  43. ncbi request reprint Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study
    Peter Hovind
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Diabetes 54:1523-7. 2005
    ....
  44. ncbi request reprint Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 31:1170-6. 2008
    ..We evaluated the association of biomarkers of endothelial dysfunction and inflammation with all-cause mortality and cardiovascular mortality and morbidity and decline in glomerular filtration rate (GFR) in type 1 diabetic patients...
  45. pmc NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Cardiovasc Diabetol 10:71. 2011
    ....
  46. ncbi request reprint Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:1258-64. 2003
    ..To assess recent trends in the cumulative incidence of diabetic microangiopathy in type 1 diabetes, we analyzed data from long-term prospective observational studies lasting >/=20 years...
  47. ncbi request reprint Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients
    Maria Lajer
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Nephrol Dial Transplant 22:3235-9. 2007
    ..Therefore, we investigated the association between two polymorphisms -381T/C and 1551G/A of the BNP gene, plasma NT-proBNP levels and mortality prognosis in 380 type 1 diabetic patients with and without diabetic nephropathy...
  48. ncbi request reprint Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 66:1180-6. 2004
    ....
  49. ncbi request reprint Remission and regression of diabetic nephropathy
    Peter Hovind
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    Curr Hypertens Rep 6:377-82. 2004
    ..However, to prevent development of ESRD in diabetic patients, an aggressive multifactorial approach, aiming at lowering blood pressure and albuminuria, and improving glycemic control, must be applied...
  50. ncbi request reprint Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes
    Andreas Kjaer
    Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    J Nucl Med 44:19-23. 2003
    ..In addition, we studied the effect of acute angiotensin-converting enzyme (ACE) inhibition on the flow response...
  51. pmc Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate
    Christel Joergensen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 35:168-72. 2012
    ..Coronary artery disease (CAD) is the major cause of morbidity and mortality in type 2 diabetic patients. Severe vitamin D deficiency has been shown to predict cardiovascular mortality in type 2 diabetic patients...
  52. ncbi request reprint Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria
    Steen Andersen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:3296-302. 2003
    ..Therefore, the present substudy of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study (IRMA-2) investigated the reversibility of kidney function changes after withdrawal of 2 years' antihypertensive treatment...
  53. doi request reprint Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    J Hypertens 31:1646-52. 2013
    ..Our aim was to determine whether urinary angiotensinogen and renin are circulating RAAS-independent markers during RAAS blockade...
  54. ncbi request reprint Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 29:1024-30. 2006
    ....
  55. ncbi request reprint Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate
    Peter Gaede
    Steno Diabetes Center, Gentofte, Copenhagen, Denmark
    Nephrol Dial Transplant 18:539-42. 2003
    ..Whether a similar effect on AER exists during low-dose ASA treatment, which may confound the diagnosis and monitoring of micro- and macroalbuminuria in type 2 diabetic patients, remains to be elucidated...
  56. pmc Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Cardiovasc Diabetol 11:119. 2012
    ..We assessed the association between P-NT-proBNP and WMH or brain atrophy measured with magnetic resonance imaging (MRI) in type 2 diabetic patients, and age-matched controls...
  57. ncbi request reprint Relation of left ventricular function, mass, and volume to NT-proBNP in type 1 diabetic patients
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 31:968-70. 2008
    ..To measure left ventricular mass (LVM), left ventricular volumes, and left ventricular function (LVF) in a cohort of type 1 diabetic patients and to correlate measures of imaging to NH(2)-terminal pro-brain natriuretic peptide (NT-proBNP)...
  58. doi request reprint Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
    Søren S Lund
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Eur J Endocrinol 158:631-41. 2008
    ..In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients...
  59. ncbi request reprint Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy
    Anders Jorsal
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 74:649-54. 2008
    ..These studies show that high serum adiponectin levels predict mortality and progression to end stage renal disease in type I diabetic patients...
  60. ncbi request reprint Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study
    Peter Rossing
    Steno Diabetes Center, Gentofte, Denmark Novo Nordisk, Biostatistics, Bagsvaerd, Denmark
    Diabetes Care 25:859-64. 2002
    ..To evaluate prospectively putative risk factors for development of microalbuminuria and macroalbuminuria in type 1 diabetes...
  61. ncbi request reprint Smoking and progression of diabetic nephropathy in type 1 diabetes
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:911-6. 2003
    ..We assessed the impact of smoking on progression of diabetic nephropathy in type 1 diabetic patients enrolled in a prospective observational cohort study started in 1983...
  62. ncbi request reprint Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy
    Per K Christensen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 26:156-62. 2003
    ..Information on the impact of calcium antagonist treatment on renal autoregulation in humans is lacking. This study examines the effect of isradipine treatment on the autoregulation of the glomerular filtration rate (GFR)...
  63. ncbi request reprint An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Eur J Endocrinol 156:83-90. 2007
    ..The aim of this study was to investigate whether an IGF-I gene promoter polymorphism influenced the development of persistent MA in type 1 diabetes...
  64. ncbi request reprint Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:193-205. 2005
    ..New insights into the pathogenesis and treatment of diabetic renal disease may emerge from recent advances in proteomics using high-throughput mass spectrometry (MS) of urine...
  65. ncbi request reprint Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy
    Henrik P Hansen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 61:163-8. 2002
    ..The aim of our study was to evaluate the diurnal variation in glomerular filtration rate (GFR), and the potential mechanisms responsible for such variations in GFR and albuminuria in diabetic nephropathy...
  66. ncbi request reprint PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Nephrol Dial Transplant 17:1408-12. 2002
    ..We tested the impact of the PC-1 (K121Q) variant on loss of glomerular filtration rate (GFR) measured by the [(51)Cr]EDTA plasma clearance technique...
  67. pmc Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study
    Peter Hovind
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes 58:1668-71. 2009
    ..Whether uric acid has a causal role in the development of diabetic nephropathy is not known. The objective of the present study is to evaluate uric acid as a predictor of persistent micro- and macroalbuminuria...
  68. pmc Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients
    Stine Elkjaer Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Diabetes Care 33:1320-4. 2010
    ..Our aim was to evaluate u-LFABP as a predictor of progression to micro- and macroalbuminuria in type 1 diabetes...
  69. ncbi request reprint Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy
    Steen Andersen
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 67:2325-9. 2005
    ..The present study aimed to investigate the short- and long term effects of angiotensin II receptor blockade by Losartan on urinary CTGF levels in hypertensive type 1 diabetic patients with diabetic nephropathy...
  70. ncbi request reprint Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy
    Henrik Post Hansen
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Kidney Int 62:220-8. 2002
    ..The purpose of our study was to determine the effect of dietary protein restriction on survival and progression to ESRD in diabetic nephropathy...
  71. ncbi request reprint Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria
    Peter Gaede
    Steno Diabetes Center, Gentofte, Denmark
    Nephrol Dial Transplant 19:2784-8. 2004
    ..However, the long-term impact of stabilization/regression in albuminuria on decline in glomerular filtration rate (GFR) has not been established...
  72. ncbi request reprint Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy
    Peter Jacobsen
    Steno Diabetes Center, Gentofte, Denmark
    Curr Opin Nephrol Hypertens 13:319-24. 2004
    ....
  73. ncbi request reprint Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
    Anne Sofie Astrup
    Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Denmark
    Diabetes Care 29:334-9. 2006
    ..Because CAN is common in patients with diabetic nephropathy, we evaluated the predictive value of CAN in type 1 diabetic patients with and without diabetic nephropathy...
  74. ncbi request reprint Long-term prevention of diabetic nephropathy: an audit
    K J Schjoedt
    Steno Diabetes Center, Niels Steensens Vej 1, 2820 Gentofte, Denmark
    Diabetologia 51:956-61. 2008
    ....
  75. doi request reprint The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP
    Stine E Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Scand J Clin Lab Invest 72:137-42. 2012
    ..We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP)...
  76. ncbi request reprint Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study
    Stine Elkjaer Nielsen
    Steno Diabetes Center, Gentofte, Denmark
    Nephron Clin Pract 118:c130-5. 2011
    ..We evaluated urinary (u)-NGAL as a predictor of progression in diabetic nephropathy in type 1 diabetic (T1D) patients...
  77. pmc Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
    Henrik Reinhard
    Steno Diabetes Center, Gentofte, Denmark
    Cardiovasc Diabetol 10:70. 2011
    ..We investigated the correlation between P-OPG and coronary artery disease (CAD) in asymptomatic type 2 diabetic patients with microalbuminuria...
  78. ncbi request reprint Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:1250-7. 2005
    ..Furthermore, end-stage renal disease (ESRD) was the main cause of death. We prospectively assessed the impact of reno- and cardiovascular protective treatment on prognosis in type 1 diabetic patients with diabetic nephropathy...
  79. doi request reprint Effect of a multifactorial intervention on mortality in type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 358:580-91. 2008
    ..We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes...
  80. ncbi request reprint Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study
    Anne Sofie Astrup
    Steno Diabetes Center, Gentofte, Denmark
    J Hypertens 25:2479-85. 2007
    ..To evaluate the prognostic significance of cardiovascular risk factors including 24-h ambulatory blood pressure level and rhythm for all-cause mortality in type 2 diabetic patients...
  81. pmc Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study
    Peter Hovind
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
    BMJ 328:1105. 2004
    ..To evaluate baseline predictors for the development of persistent microalbuminuria and macroalbuminuria prospectively in patients with type 1 diabetes...
  82. ncbi request reprint Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study
    Frederik Persson
    Steno Diabetes Center, Gentofte, Denmark
    Scand J Clin Lab Invest 68:731-8. 2008
    ....
  83. ncbi request reprint Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy
    K J Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Scand J Clin Lab Invest 66:173-80. 2006
    ....
  84. ncbi request reprint Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
    F Persson
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 73:1419-25. 2008
    ..Our study shows that aliskiren reduced 24 h SBP, and this was associated with a reduction in albuminuria in type 2 diabetic patients...
  85. ncbi request reprint Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
    K J Schjoedt
    Steno Diabetes Center, Niels Steensens Vej 2, 2820, Gentofte, Denmark
    Diabetologia 47:1936-9. 2004
    ..We evaluated the influence of plasma aldosterone levels on progression of diabetic nephropathy during long-term blockade of the renin-angiotensin-aldosterone system...
  86. doi request reprint Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus
    Søren S Lund
    Steno Diabetes Center, Gentofte, Denmark
    Clin Chem 57:298-308. 2011
    ..LDL cholesterol (LDL-C) is a modifiable cardiovascular disease risk factor. We used 3 LDL-C methods to study the agreement between fasting and postprandial LDL-C in type 2 diabetes (T2DM) patients...
  87. pmc Tubular and glomerular injury in diabetes and the impact of ACE inhibition
    Stine E Nielsen
    Steno Diabetes Center, Copenhagen, Denmark
    Diabetes Care 32:1684-8. 2009
    ..Subsequently, we evaluated the effect of ACE inhibition on U-LFABP in patients with diabetic nephropathy...
  88. ncbi request reprint PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites
    Gitte Andersen
    Steno Diabetes Center, Niels Steensens Vej 2, NSH2 16, DK 2820 Gentofte, Denmark
    Hypertension 45:565-70. 2005
    ..001). In conclusion, the Ser allele of PGC-1alpha Gly482Ser confers a significantly reduced risk of hypertension in whites. Further studies are needed to elucidate the differential role of this polymorphism in men and women...
  89. ncbi request reprint Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients
    M Lajer
    Steno Diabetes Center, Gentofte, Denmark
    Diabet Med 23:675-80. 2006
    ..Therefore, we investigated whether the -344T/C polymorphism is associated with the development and progression of diabetic nephropathy in Type 1 diabetes mellitus...
  90. ncbi request reprint Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
    L Tarnow
    Steno Diabetes Center, Niels Steensens Vej 2, DK 2820, Gentofte, Denmark
    Diabetologia 49:2256-62. 2006
    ..Elevated NT-proBNP predicts excess morbidity and mortality in diabetic patients with an elevated urinary albumin excretion rate. This study investigated the prognostic value of NT-proBNP in a cohort of type 2 diabetic patients...
  91. ncbi request reprint Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
    P Gaede
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetologia 48:156-63. 2005
    ..We examined whether plasma N-terminal probrain natriuretic peptide (NT-proBNP) predicts cardiovascular outcome in patients with type 2 diabetes...
  92. ncbi request reprint Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
    K J Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 70:536-42. 2006
    ....
  93. ncbi request reprint Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy
    L Tarnow
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Diabetologia 48:149-55. 2005
    ..This study investigated the prognostic value of NT-proBNP in a large cohort of type 1 diabetic patients with and without diabetic nephropathy...
  94. doi request reprint Microalbuminuria and obesity: impact on cardiovascular disease and mortality
    Klaus Peder Klausen
    The Copenhagen City Heart Study, Epidemiological Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark
    Clin Endocrinol (Oxf) 71:40-5. 2009
    ..We also aimed to determine the risk of death and CVD at different levels of microalbuminuria and obesity...
  95. ncbi request reprint Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients
    Lars Melholt Rasmussen
    Department of Clinical Biochemistry, University Hospital of Aarhus, Aarhus Amtssygehus, T Hansengade 2, DK 8000 Aarhus C, Denmark
    Eur J Endocrinol 154:75-81. 2006
    ..OPG is present in the circulation, where increased amounts have been observed in patients with diabetes. In this study, we examined whether plasma OPG is associated with the glycaemic and vascular status of patients with type 1 diabetes...
  96. ncbi request reprint Association between mannose-binding lectin and vascular complications in type 1 diabetes
    Troels K Hansen
    Immunoendocrine Research Unit, Medical Department M Endocrinology and Diabetes, Aarhus University Hospital, Norrebrogade 42 44, DK 8000 Aarhus C, Denmark
    Diabetes 53:1570-6. 2004
    ....
  97. ncbi request reprint Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications
    Per Flesner
    Department of Ophthalmology, Herlev University Hospital, Copenhagen, Denmark
    Acta Ophthalmol Scand 80:19-24. 2002
    ..The lens fluorescence and the blood-aqueous barrier (BAB) were then evaluated as experimental preoperative risk indicators...
  98. ncbi request reprint Beneficial impact of spironolactone in diabetic nephropathy
    Katrine Jordan Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:2829-36. 2005
    ..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
  99. pmc Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study
    Søren Søgaard Lund
    Steno Diabetes Center, Gentofte, Denmark
    PLoS ONE 3:e3363. 2008
    ..We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control...
  100. ncbi request reprint Mannose-binding lectin and mortality in type 2 diabetes
    Troels Krarup Hansen
    Immunoendocrine Research Unit, Medical Department M and Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark
    Arch Intern Med 166:2007-13. 2006
    ..We evaluated the relationship between serum MBL and mortality and development of albuminuria in type 2 diabetes...
  101. ncbi request reprint The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy
    A Jorsal
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    Mol Genet Metab 94:347-51. 2008
    ..4 years [mean+/-SD], duration of diabetes 28.3+/-8.8 years, GFR 66+/-8.8 ml/min) and 428 patients with longstanding type 1 diabetes and persistent normoalbuminuria (230 men; age 45.4+/-11.6 years, duration of diabetes 27.8+/-10.1 years)...